Vaccines Radar: Weekly Must-Knows
From scalable innovations to localized action, this episode explores how technology, policy, and public health goals are coming together to shape the future of immunization
🧬 Ethris and Lonza are tackling cold-chain barriers with a nasally delivered, spray-dried mRNA flu vaccine targeting mucosal immunity.
🐶 AIM’s serum-free rabies vaccine is gearing up for market launch—eliminating animal-derived components and projected to disrupt a market set to reach RMB 14.8 billion by 2030.
🧪 South Korea’s Barythrax became the first recombinant anthrax vaccine, approved after demonstrating long-term immunity with zero residual toxins.
🇨🇳 China begins clinical trials for its first domestically developed mpox vaccine, responding swiftly to global outbreak risks.
🇨🇮 Côte d’Ivoire’s massive HPV campaign targets 3.5 million girls in just one week—bridging gaps in access and transforming cervical cancer prevention.
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine research
#VaccineInnovation #MpoxVaccine #RabiesVaccine #HPVCampaign #AnthraxVaccine #mRNAtechnology #BiotechNews #PublicHealth #ClinicalTrials #GlobalImmunization #LucidQuest #DigitalHealth #VaccineUpdates #GlobalHealthSecurity